Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 1, 2026 · Multiple disclosures including leadership change and material agreement
| ItemItem | Disclosure |
|---|---|
| Item 1.01 | Entered a material definitive agreement |
| Item 3.02 | Item 3.02 |
| Item 5.01 | Item 5.01 |
| Item 5.02 | Director or executive officer departure or appointment |
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 9.01 | Financial statements and exhibits |
Rallybio Corp filed this to disclose a change in directors or executive officers appointments, departures, or role changes that can signal a strategic shift.
1 Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement Combined company to operate as Avenzo Therapeutics, advancing a leading portfolio of next-generation oncology therapies, including small molecules and antibody-drug conjugates Concurrent oversubscribed private placement financing of $215 million with participation from leading syndicate of healthcare institutional investors and mutual funds Private plac…
This filing reports Item 1.01 (entered a material definitive agreement); Item 5.02 (director or executive officer departure or appointment). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
Rallybio Corp reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
